stockrowEnliven Therapeutics, Inc.
ELVN Healthcare Biotechnology
- EPS
- 0.00%
- Free cash flow
- −8.34%
Quarter to June 2026, against a year earlier
Follow ELVN
Alert me
Enliven Therapeutics, Inc. (ELVN) Return on equity
Enliven Therapeutics, Inc.'s return on equity over the twelve months to 30 June 2026 was −15.3%, up 11.6 percentage points from fiscal 2025 (−27.0%). Over the past ten years it has ranged from −818.3% (fiscal 2022) to 62.4% (fiscal 2019); the current reading is higher than 67% of that period. That is above the Biotechnology industry median of −50.1% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −27.0% | 5.09 |
| FY2024 | −32.0% | 52.63 |
| FY2023 | −84.7% | 733.62 |
| FY2022 | −818.3% | (758.00) |
| FY2021 | −60.3% | 216.32 |
| FY2020 | −276.6% | (339.04) |
| FY2019 | 62.4% | 8.25 |
| FY2018 | 54.2% | 54.18 |
| FY2017 | 0.00% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | 31.4% |
| VRDN Viridian Therapeutics, Inc. compare | 0.00% |
| TLX Telix Pharmaceuticals Limited compare | 0.00% |
| ELVN Enliven Therapeutics, Inc. | −15.3% |
| DNLI Denali Therapeutics Inc. compare | −33.9% |
| DYN Dyne Therapeutics, Inc. compare | −81.6% |
| VKTX Viking Therapeutics, Inc. compare | −96.4% |
| TARS Tarsus Pharmaceuticals, Inc. compare | −319.8% |
| CELC Celcuity, Inc. compare | −1,433.7% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)